JP2020532572A5 - - Google Patents
Info
- Publication number
- JP2020532572A5 JP2020532572A5 JP2020513799A JP2020513799A JP2020532572A5 JP 2020532572 A5 JP2020532572 A5 JP 2020532572A5 JP 2020513799 A JP2020513799 A JP 2020513799A JP 2020513799 A JP2020513799 A JP 2020513799A JP 2020532572 A5 JP2020532572 A5 JP 2020532572A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- antibody
- sequence described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023076556A JP2023103315A (ja) | 2017-09-06 | 2023-05-08 | 癌の診断に有用な抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2017/072386 WO2019048040A1 (en) | 2017-09-06 | 2017-09-06 | ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER |
| EPPCT/EP2017/072386 | 2017-09-06 | ||
| PCT/EP2018/073883 WO2019048489A1 (en) | 2017-09-06 | 2018-09-05 | ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076556A Division JP2023103315A (ja) | 2017-09-06 | 2023-05-08 | 癌の診断に有用な抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532572A JP2020532572A (ja) | 2020-11-12 |
| JP2020532572A5 true JP2020532572A5 (enExample) | 2022-04-27 |
| JP7277439B2 JP7277439B2 (ja) | 2023-05-19 |
Family
ID=59858709
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513799A Active JP7277439B2 (ja) | 2017-09-06 | 2018-09-05 | 癌の診断に有用な抗体 |
| JP2023076556A Pending JP2023103315A (ja) | 2017-09-06 | 2023-05-08 | 癌の診断に有用な抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076556A Pending JP2023103315A (ja) | 2017-09-06 | 2023-05-08 | 癌の診断に有用な抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11279757B2 (enExample) |
| EP (2) | EP3679069B1 (enExample) |
| JP (2) | JP7277439B2 (enExample) |
| KR (2) | KR20230107371A (enExample) |
| CN (3) | CN111406070A (enExample) |
| AU (2) | AU2018327587B2 (enExample) |
| BR (1) | BR112020003694B1 (enExample) |
| CA (1) | CA3073157A1 (enExample) |
| ES (1) | ES2998108T3 (enExample) |
| IL (2) | IL293017A (enExample) |
| MX (2) | MX393242B (enExample) |
| PL (1) | PL3679069T3 (enExample) |
| SG (1) | SG11202000961SA (enExample) |
| WO (2) | WO2019048040A1 (enExample) |
| ZA (1) | ZA202000851B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| WO2019048040A1 (en) | 2017-09-06 | 2019-03-14 | Ganymed Pharmaceuticals Gmbh | ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER |
| SG11202001430SA (en) | 2017-09-29 | 2020-04-29 | Daiichi Sankyo Co Ltd | Antibody-pyrrolobenzodiazepine derivative conjugate |
| MA54955A (fr) | 2019-02-15 | 2021-12-22 | Integral Molecular Inc | Anticorps anti-claudine 6 et leurs utilisations |
| CN117222672A (zh) | 2021-04-22 | 2023-12-12 | 安斯泰来制药株式会社 | 抗cldn4-抗cd137双特异性抗体 |
| EP4626933A1 (en) | 2022-11-30 | 2025-10-08 | Integral Molecular, Inc. | Antibodies directed to claudin 6, including bispecific formats thereof |
| CN121793985A (zh) | 2023-05-25 | 2026-04-03 | 加利福尼亚大学校董会 | 治疗癌症的方法 |
| WO2025146161A1 (en) * | 2024-01-04 | 2025-07-10 | Hansoh Bio Llc | Antibody, antigen-binding fragment and medical use thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| IL155977A0 (en) | 2000-11-30 | 2003-12-23 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| KR20110017020A (ko) | 2002-10-17 | 2011-02-18 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| EP1668035A2 (en) * | 2003-09-11 | 2006-06-14 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
| WO2008013948A2 (en) * | 2006-07-27 | 2008-01-31 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
| NZ601022A (en) * | 2006-10-12 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Diagnosis and treatment of cancer using anti-ereg antibody |
| WO2009028663A1 (ja) * | 2007-08-30 | 2009-03-05 | Kyowa Hakko Kirin Co., Ltd. | 抗Claudin-3抗体 |
| US9274119B2 (en) | 2008-01-11 | 2016-03-01 | The University Of Tokyo | Anti-CLDN6 antibody |
| EP2322555A1 (en) * | 2009-11-11 | 2011-05-18 | Ganymed Pharmaceuticals AG | Antibodies specific for claudin 6 (CLDN6) |
| RU2675997C2 (ru) * | 2009-11-11 | 2018-12-25 | Ганимед Фармасьютикалз Аг | Антитела, специфичные к клаудину 6 (cldn6) |
| EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| RS58087B1 (sr) * | 2011-05-13 | 2019-02-28 | Ganymed Pharmaceuticals Gmbh | Antitela za lečenje kancera koji eksprimira klaudin 6 |
| WO2015014376A1 (en) * | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
| GB201607534D0 (en) * | 2016-04-29 | 2016-06-15 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| WO2019048040A1 (en) | 2017-09-06 | 2019-03-14 | Ganymed Pharmaceuticals Gmbh | ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER |
-
2017
- 2017-09-06 WO PCT/EP2017/072386 patent/WO2019048040A1/en not_active Ceased
-
2018
- 2018-09-05 IL IL293017A patent/IL293017A/en unknown
- 2018-09-05 PL PL18765858.8T patent/PL3679069T3/pl unknown
- 2018-09-05 CA CA3073157A patent/CA3073157A1/en active Pending
- 2018-09-05 EP EP18765858.8A patent/EP3679069B1/en active Active
- 2018-09-05 EP EP24212659.7A patent/EP4512830A3/en active Pending
- 2018-09-05 SG SG11202000961SA patent/SG11202000961SA/en unknown
- 2018-09-05 KR KR1020237021589A patent/KR20230107371A/ko active Pending
- 2018-09-05 KR KR1020207005756A patent/KR102550489B1/ko active Active
- 2018-09-05 CN CN201880058261.5A patent/CN111406070A/zh active Pending
- 2018-09-05 AU AU2018327587A patent/AU2018327587B2/en active Active
- 2018-09-05 CN CN202210691319.8A patent/CN115433283B/zh active Active
- 2018-09-05 MX MX2020002243A patent/MX393242B/es unknown
- 2018-09-05 US US16/641,160 patent/US11279757B2/en active Active
- 2018-09-05 WO PCT/EP2018/073883 patent/WO2019048489A1/en not_active Ceased
- 2018-09-05 BR BR112020003694-3A patent/BR112020003694B1/pt active IP Right Grant
- 2018-09-05 CN CN202410880523.3A patent/CN118852435A/zh active Pending
- 2018-09-05 ES ES18765858T patent/ES2998108T3/es active Active
- 2018-09-05 JP JP2020513799A patent/JP7277439B2/ja active Active
-
2020
- 2020-02-05 IL IL272487A patent/IL272487B/en unknown
- 2020-02-10 ZA ZA2020/00851A patent/ZA202000851B/en unknown
- 2020-02-27 MX MX2022007706A patent/MX2022007706A/es unknown
-
2022
- 2022-02-07 US US17/666,122 patent/US11919951B2/en active Active
-
2023
- 2023-05-08 JP JP2023076556A patent/JP2023103315A/ja active Pending
- 2023-07-28 AU AU2023208203A patent/AU2023208203A1/en active Pending
-
2024
- 2024-01-26 US US18/423,761 patent/US20240209079A1/en active Pending